On April 9, Wondfo Biotech (300482.SZ) released its 2024 Annual Report, reporting total revenue of RMB 3.065 billion, up 10.85% year-on-year, and net profit attributable to shareholders of RMB 562 million, an increase of 15.18% year-on-year.


 
Strong Growth Across Core Business Segments with Improved Quality and Scale
 
With a comprehensive product portfolio and well-integrated business segments, Wondfo achieved strategic synergies through vertical integration and horizontal sharing across its supply chain and marketing systems. In 2024, the company’s four growth engines achieved great performance.


 
Accelerating IPD Transformation and Launching High-Impact New Products
 
Wondfo continued to advance its Integrated Product Development (IPD) transformation, leveraging its three core technology platforms—immunoassay, molecular diagnostics, and electrochemistry. The company built a differentiated “platform + scenario” product matrix around seven key disease areas: cardiovascular & metabolic diseases, oncology, respiratory diseases, infectious diseases, maternal & child health, drug testing, and diabetes.
 
In 2024, R&D investment reached RMB 438 million, representing 14.3% of revenue. Wondfo launched 82 new products—75 reagents and 7 devices.



For chemiluminescence platform, the FC-2100 fully automated analyzer quickly gained traction in both domestic and international markets.
 
For immunofluorescence platform, Wondfo upgraded FS-1000 and FS-2000, analyzers delivered shorter turnaround times and improved sensitivity and specificity.
 
Accelerating Globalization and Advancing Innovative Consumer and AI Diagnostics
 
Wondfo made significant progress in its internationalization strategy, with overseas revenue achieving rapid year-on-year growth. By deepening its presence in developing countries along the Belt and Road Initiative, Wondfo built a competitive edge in small and mid-sized medical institutions. It also made key breakthroughs in medium-sized third-party laboratories and in-hospital emergency settings, with notable success in expanding immunofluorescence and single-test chemiluminescence applications.
 
In Innovation-Driven Business Development, Wondfo Achieved Major Breakthroughs
 
Molecular Diagnostics: The company independently developed fully automated nucleic acid amplification system for both medium throughput and POCT applications. Meanwhile, continuously develop new products tailored to the platform, while driving core technology innovation and accelerating global market expansion. Several test items have received regulatory approval and launched successfully.
 
Pathology: Wondfo is paving the way for “Digital Pathology + AI” in clinical practice.
 
Consumer Diagnostics: Wondfo’s WELLlife™ COVID-19/Flu A&B Home Test received FDA approval in 2024, achieving rapid growth via e-commerce and pharmacy channels. It was also named “China’s Leading Brand in Infectious Disease Rapid Testing” and “Top-Selling HIV/STD Test Brand”by iiMedia Research.
 

Looking Ahead


Racing for life, Wondfo is dedicated to becoming a globally trusted IVD company, advancing biotechnology to benefit society.